A multicenter, open-label, noninterventional study to evaluate the impact on clinical effects, user-friendliness and patients’ acceptance of AirFluSal Forspiro in the treatment of asthma under real-life conditions (ASSURE)
Received 9 January 2019
Accepted for publication 12 April 2019
Published 24 May 2019 Volume 2019:10 Pages 29—39
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 3
Editor who approved publication: Professor David B Price
Vibeke Backer,1 Leif Bjermer,2 Olav Kåre Refvem,3 Andreas Søderman,4 Spencer Jones5
1Department of Respiratory Medicine, Bispebjerg Hospital, Copenhagen University, 48 2400 Copenhagen, Denmark; 2Department of Respiratory Medicine and Allergology, Skåne University Hospital, 221 85 Lund, Sweden; 3Lungepraksis AS, Oslo 0873, Norway; 4Medical Affairs Nordics, Sandoz AS, Copenhagen, DK-2300, Denmark; 5Global Medical Affairs, Sandoz International GmbH, Holzkirchen, D-83607, Germany
Background: The design of inhaler devices may potentially influence adherence/persistence and outcomes in asthma.
Objective: The primary objective was to assess asthma control and any change in the quality of life in patients using an intuitive dry powder inhaler containing fluticasone propionate/salmeterol (AirFluSal®, Forspiro®,) for the treatment of asthma in everyday practice.
Methods: ASSURE was a multicenter, noninterventional, open-label, prospective study in patients with asthma, aged ≥12 years and treated with the Forspiro device in Denmark, Sweden and Norway. Patients’ opinions of their asthma control were assessed by the Asthma Control Test (ACT) questionnaire and asthma-related quality of life by the Mini Asthma Quality of Life Questionnaire (miniAQLQ) at baseline and at two follow-up visits (approximately 4–8-week intervals).
Results: Of 321 patients enrolled in the study, 299 received at least one dose of fluticasone propionate/salmeterol via the Forspiro device and 204 had evaluable data at the baseline visit and at least one later visit. Patients showed improvements in asthma control and quality of life during the study. The mean sum score of ACT increased from 18.0 (SD 4.5) at visit 1 to 19.9 (4.2) at visit 2 and 20.5 (4.3) at visit 3. Overall, 38.2% of patients improved by the minimal clinically important difference (MCID) of ≥3 points (45.6% among those with a baseline score below 23 [ie, not already well controlled]). The mean score on the miniAQLQ increased from 5.16 (SD 1.24) at visit 1 to 5.58 (SD 1.20) at visit 2 and 5.82 (SD 1.04) at visit 3. Overall, 42.6% of patients improved by the MCID of ≥0.5.
Conclusion: This real-life study suggests that treatment with fluticasone propionate/salmeterol via the Forspiro device can improve asthma symptom control and quality of life.
Keywords: asthma, fluticasone propionate, salmeterol, symptom control, quality of life
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]